Notes to the Consolidated Financial Statements continued 10.
Dividends 2018 2017 m m Final dividend paid in respect of prior year but not recognised as a liability in that year: 15.33 pence per share 2017: 12.91 pence per share 14.3 12.0 Interim dividend paid: 7.33 pence per share 2017: 6.11 pence per share 7.5 5.7 Total dividend 22.66 pence per share 2017: 19.02 pence per share recognised as distributions to equity holders in the period 21.8 17.7 Proposed final dividend for the year ended 30 June 2018: 18.17 pence per share 2017: 15.33 pence per share 18.6 14.3 Total dividend paid and proposed for the year ended 30 June 2018: 25.50 pence per share 2017: 21.44 pence per share 26.1 20.0 In accordance with IAS 10 Events After the Balance Sheet Date, the proposed final dividend for the year ended 30 June 2018 has not been accrued for in these financial statements.
It will be shown as a deduction from equity in the financial statements for the year ending 30 June 2019.
There are no income tax consequences.
The final dividend for the year ended 30 June 2017 is shown as a deduction from equity in the year ended 30 June 2018.
At 30 June 2018, the distributable reserves of Dechra Pharmaceuticals PLC as determined under UK company law is 120.4 million 2017: 66.4 million.
Earnings per Share Earnings per ordinary share has been calculated by dividing the profit attributable to equity holders of the parent after taxation for each financial period by the weighted average number of ordinary shares in issue during the period.
2018 2017 Pence Pence Basic earnings per share Underlying 76.85 64.68 Basic 37.24 28.09 Diluted earnings per share Underlying 76.45 64.33 Diluted 37.04 27.93 The calculations of basic and diluted earnings per share are based upon: 2018 2017 m m Earnings for underlying basic and underlying diluted earnings per share 74.5 60.1 Earnings for basic and diluted earnings per share 36.1 26.1 Number Number Weighted average number of ordinary shares for basic earnings per share 96,942,002 92,962,967 Impact of share options 509,209 516,032 Weighted average number of ordinary shares for diluted earnings per share 97,451,211 93,478,999 Underlying measures exclude non-underlying items as defined in the Consolidated Income Statement on page 111.
At 30 June 2018, there are 231,551 options 2017: 294,848 that are excluded from the EPS calculations as they are not dilutive for the period presented but may become dilutive in the future.
130 Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2018 www.
